Altered innate and adaptive immune responses in patients with hidradenitis suppurativa

British Journal of Dermatology

Volumn 156, Issue 1, 2007, Pages 51-56

  Giamarellos Bourboulis, E J ^a   Antonopoulou, A ^a   Petropoulou, C ^a   Mouktaroudi, M ^a   Spyridaki, E ^a   Baziaka, F ^a   Pelekanou, A ^a   Giamarellou, H ^a   Stavrianeas, N G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cytokines; Hidradenitis; Lymphocytes; Monocytes

Indexed keywords

ENDOTOXIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; BREAST; CD8+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INNATE IMMUNITY; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NATURAL KILLER CELL; PATHOGENESIS; PERINEUM; PRIORITY JOURNAL; SUPPURATIVE HIDRADENITIS;

ADULT; FEMALE; FLOW CYTOMETRY; HIDRADENITIS SUPPURATIVA; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-6; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MONOCYTES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845543681     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07556.x     Document Type: Article

References (15)

1. von der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001; 144:809-13.
2. Slade DEM, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 2003; 56:451-61.
3. Wiseman MC. Hidradenitis suppurativa: a review. Dermatol Ther 2004; 17:50-4.
4. Sullivan TP, Welsh E, Kerdel FA et al. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003; 149:1046-9.
5. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatol Ther 2005; 16:58-61.
6. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006; 154:726-9.
7. Shah N. Hidradenitis suppurativa: a treatment challenge. Am Fam Physician 2005; 1554:1547-52.
8. Dvorak VC, Root RK, MacGregor RR. Host-defense mechanisms in hidradenitis suppurativa. Arch Dermatol 1977; 113:450-3.
9. Lapins J, Asman B, Gustafsson A et al. Neutrophil-related host response in hidradenitis suppurativa: a pilot study in patients with inactive disease. Acta Derm Venereol 2001; 81:96-9.
10. Ginder PA, Ousley M, Hinthorn D et al. Hidradenitis suppurativa: evidence for a bactericidal defect correctable by cholinergic agonist in vitro and in vivo. J Clin Immunol 1982; 2:237-41.
11. O'Loughlin S, Woods R, Kirke PN et al. Hidradenitis suppurativa. Glucose tolerance, clinical, microbiologic, and immunologic features and HLA frequencies in 27 patients. Arch Dermatol 1988; 124:1043-6.
12. Jemec GB. Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother 2004; 5:1767-70.
13. Jemec GBE. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol 2002; 27:528-9.
14. Ah-Weng A, Langtry JAA, Velangi S et al. Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol 2005; 30:669-71.
15. Kagan RJ, Yakuboff KP, Warner P et al. Surgical treatment of hidradenitis suppurativa: a 10-year experience. Surgery 2005; 138:734-41.